# US 8,278,277 B2 · Delivery of hydrophilic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,277 B2
- Document ID: US8278277B2
- Status: Granted
- Kind: B2
- Application number: 12/420,896
- Filed: 2009-04-09
- Published: 2010-09-02
- Granted: 2012-10-02
- Earliest claimed: 2009-03-02
- Assignees: University College London
- Inventors: Ijeoma Uchegbu; Aikaterini Lalatsa; Andreas Schatzlein
- Web page: https://patentgrep.com/patent/US8278277B2

## CPC

- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S 977/788: Of specified organic or carbon-based composition
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.

## Claims

### Claim 1

A composition comprising a lipophilic derivative of the hydrophilic neuropeptide Leucine[5]-Enkephalin and an amphiphile compound,
wherein the derivative comprises a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine[5]-Enkephalin, wherein the linker is of the formula —C(C═O)R1, wherein R1 is C4-20 alkyl;
wherein the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ); and
wherein the composition is formulated for human or animal administration by all routes except for the topical route.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the ratio of amphiphile compound to Leucine[5]-Enkephalin derivative in the composition is around 5:1.

### Claim 3

A pharmaceutical composition comprising a lipophilic derivative of the hydrophilic neuropeptide Leucine[5]-Enkephalin, an amphiphile compound and one or more pharmaceutically acceptable excipients,
wherein the derivative comprises a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine[5]-Enkephalin, wherein the linker is of the formula —C(C═O)R1, wherein R1 is C4-20 alkyl;
wherein the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ); and
wherein the composition is formulated for human or animal administration by all routes except for the topical route.

### Claim 4 (depends on 1)

A method of medical treatment of a condition in a human or animal body, said condition being selected from the group of schizophrenia, obesity, pain and sleep disorders, and psychiatric diseases, said method comprising the administration to a human or animal body in need of said treatment a composition according to claim 1 wherein the composition is not administered via topical route.

### Claim 5 (depends on 4)

A method according to claim 4, wherein the composition is orally or intravenously administered to the human or animal body.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the composition is formulated for administration via a route selected from gastrointestinal delivery, parenteral delivery, or mucosal delivery.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the composition is administered to the human or animal body via gastrointestinal delivery, parenteral delivery, or mucosal delivery.
